SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (554)7/9/2001 9:14:04 PM
From: Scott H. Davis  Respond to of 804
 
What I find encouraging is the long term prospects as the analogues develop - if there is good dose related efficacy coupled with a better side effects profile, in a med without the name baggage, thus the Euro opportunity, while the company is not burning cash. Probably inherantly obvious to most followers here. Anyway, a pretty good risk/reward climate for long term longs, IMSCO

Scott



To: Biomaven who wrote (554)7/11/2001 2:07:12 PM
From: Vector1  Read Replies (1) | Respond to of 804
 
Peter, it looks from the IMS data that scipts will be up 10% for the q sequentially but that size of dose will be down 4%.
V1


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News